Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Treatment of recurrent oligometastatic prostate cancer may be enhanced by the addition of
Hydroxychloroquine to the current treatment regimens. Potential benefits of
Hydroxychloroquine include delayed disease progression and delayed initiation of androgen
deprivation therapy (ADT), thus lessening morbidity, distressing side effects, and improving
functioning and quality of life in men with recurrent prostate cancer.
Building on prior research at Markey, patients recently diagnosed with recurrent
oligometastatic prostate cancer will be approached about participating in this study. Per
standard of care, these patients undergo either surgery or radiation, in addition
participants of this clinical trial will also receive Hydroxychloroquine (400 mg per day,
oral medication) for 3 months.
It is expected that a participant will exhibit a 50% increase of tumor suppressor PAR-4, as
well as few, if any, negative side effects from Hydroxychloroquine.